Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-11-25
|
sirukumab |
giant cell arteritis |
3 |
GSK (UK) |
Inflammatory diseases |
2015-11-23
|
cobimetinib in combination with Zelboraf® (vemurafenib) |
previously untreated BRAF V600 mutation-positive advanced melanoma |
3 |
Roche (Switzerland) Exelixis (USA - CA) |
Cancer - Oncology |
2015-11-23
|
ofatumumab (Arzerra®) |
follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen |
3 |
Genmab (Denmark) |
Cancer - Oncology - Rare diseases |
2015-11-23
|
BL-8040 in combination with standard of care immunosuppressive therapy |
hypoplastic myelodysplastic syndrome (hMDS), aplastic anemia |
1-2 |
BiolineRx (Israel) |
Autoimmune diseases |
2015-11-23
|
ASN100 |
hospital associated S. aureus infections |
1 |
Arsanis Biosciences (Austria) |
Infectious diseases |
2015-11-21
|
CA4P (fosbretabulin tromethamine) and bevacizumab |
ovarian cancer |
2-3 |
Mateon Therapeutics (USA - CA) |
Cancer - Oncology |
2015-11-20
|
GLPG1972 |
osteoarthritis |
1 |
Galapagos (Belgium) Servier (France) |
Rheumatic diseases - Inflammatory diseases – Bone diseases |
2015-11-19
|
inecalcitol |
chronic myeloid leukemia (CML) |
preclinical |
Hybrigenics (France) |
Cancer - Oncology |
2015-11-19
|
SENS-111 |
inner-ear pathologies |
1b |
Sensorion (France) |
Otorhinolaryngology |
2015-11-18
|
AZD2811 |
advanced solid tumours |
1 |
AstraZeneca (UK) Bind Therapeutics (USA - MA) |
Cancer - Oncology |
2015-11-18
|
Keytruda® (pembrolizumab) and talimogene Laherparepvec |
carcinoma of the head and neck |
1b/3 |
Amgen (USA - CA) Merck&Co (USA - NJ) |
Cancer - Oncology |
2015-11-18
|
AGS67E |
acute myeloid leukemia |
1 |
Astellas Pharma (Japan) Agensys (USA - CA) |
Cancer - Oncology |
2015-11-18
|
Jetrea® (ocriplasmin) |
symptomatic vitreomacular adhesion or vitreomacular traction (VMT) including macular hole |
3 |
Thrombogenics (Belgium) |
Ophtalmological diseases |
2015-11-17
|
sequencing platform |
|
|
Integragen (France) Institut Gustave Roussy (France) |
Cancer - Oncology - Diagnostic |
2015-11-17
|
Vacc-4x |
HIV infection |
2 |
Bionor Pharma (Norway) |
Infectious diseases |
2015-11-17
|
bertilimumab |
moderate-to-severe ulcerative colitis |
2 |
Immune Pharmaceuticals (Israel - USA) |
Autoimmune diseases - Inflammatory diseases |
2015-11-16
|
Daklinza® (daclatasvir), sofosbuvir and ribavirin |
genotype 3 hepatitis C (HCV) patients with advanced fibrosis or cirrhosis |
3b |
BMS (USA - NY) |
Infectious diseases |
2015-11-16
|
Iluvien® |
diabetic macular edema |
3 |
Alimera Sciences (USA - GA) |
Ophtalmological diseases |
2015-11-15
|
ORY-1001 |
relapsed or refractory acute leukemia |
1 |
Oryzon Genomics (Spain) |
Cancer - Oncology |
2015-11-14
|
SPK-RPE65 |
RPE65-mediated inherited retinal dystrophies |
3 |
Spark Therapeutics (USA - PA) |
Ophtalmological diseases - Genetic diseases - Rare diseases |